Xeltis, an Eindhoven, Netherlands-based developer of implants that enable the natural creation of living and long-lasting vessels, raised additional €12.5M in final close of D2 funding.
The round, which brought the total amount to €44.5M, saw participation from European Innovation Council (EIC) Fund.
Its investors included DaVita Venture Group, EQT Life Sciences, Kurma Partners, VI Partners, and Ysios Capital, as well as Grand Pharma Group and several public and private investors.
The company intends to use the funds to support the continued clinical development of its implants.
Led by CEO Eliane Schutte, Xeltis is a medtech company developing implants that enable the natural creation of living and long-lasting vessels. Its proprietary endogenous tissue restoration (ETR) platform utilizes an advanced polymer implant which regenerates the patient’s own tissue before gradually being absorbed and leaving new, living and long-lasting vessels in place. Xeltis’ product currently under clinical development is aXessTM, an implantable blood vessel for hemodialysis vascular access.
FinSMEs
14/08/2023